Global Platform WuXi Biologics provides a truly end-to-end biologics platform with a strong one-stop service offering and a global supply chain. With planned capacity exceeding 430,000 liters across the US, China, Ireland, Germany, and Singapore after 2024, the company can support partners from discovery to commercial manufacturing, reducing development risk and enabling scalable, global production.

ESG Leadership Awarded Industry ESG Leader and Regional ESG Leader for 2026 by Morningstar Sustainalytics, WuXi Biologics demonstrates a strong sustainability profile. This can help clients meet ESG diligence and reporting requirements when selecting a biologics partner, especially for sustainability-focused programs.

Manufacturing Excellence Recent Life Sciences Industry Awards recognize WuXi Biologics Ireland site for Overall Excellence in Life Sciences and the MSAT team's Life Sciences Team of the Year, underscoring capabilities in manufacturing science, technology transfer, operational performance, and on-time delivery—key factors for customers requiring reliable scaling and technology transfer to commercial manufacturing.

Partnership Growth The company actively engages partners and markets through events like CRDMO Day in Japan and partnerships such as with Viridian Therapeutics for manufacturing, signaling a growth-oriented partnership development approach and potential opportunities to co-develop or scale upcoming biologics programs.

Scale and Revenue With revenue in the 1B-10B range, a workforce of 1001-5000, and a global footprint, WuXi Biologics has the scale to undertake large programs, invest in capacity expansions, and support long-term partnerships across multiple regions.